Skip to content
10-Q

Quarterly Report

APELLIS PHARMACEUTICALS, INC.

0000950170-25-064976

← back to feed
Filed
May 7, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · Apr 30, 2025 125.68M sh
Current Liabilities Q1 2025 · Mar 31, 2025 $178.38M
Current Liabilities Q1 2025 · Dec 31, 2024 $185.51M
Total Liabilities Q1 2025 · Mar 31, 2025 $643.07M
Total Liabilities Q1 2025 · Dec 31, 2024 $656.51M
Current Assets Q1 2025 · Mar 31, 2025 $727.72M
Current Assets Q1 2025 · Dec 31, 2024 $788.95M
Total Assets Q1 2025 · Mar 31, 2025 $807.29M
Total Assets Q1 2025 · Dec 31, 2024 $885.05M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $411.29M
Cash And Equivalents Q1 2025 · Mar 31, 2024 $325.92M
Shares Diluted restated Q1 2025 · Mar 31, 2024 122.96M sh
Capex Q1 2025 · Mar 31, 2024 $293K
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$132.98M
Stockholders Equity Q1 2025 · Mar 31, 2024 $266.68M
Stockholders Equity Q1 2025 · Dec 31, 2023 $194.52M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.54
Eps Basic Q1 2025 · Mar 31, 2024 −$0.54
Sga Expense Q1 2025 · Mar 31, 2024 $129.51M
Rd Expense Q1 2025 · Mar 31, 2024 $84.7M
Net Income Q1 2025 · Mar 31, 2024 −$66.42M
Operating Income Q1 2025 · Mar 31, 2024 −$62.09M
Revenue Q1 2025 · Mar 31, 2024 $172.33M